Pluri is a bio-technology company focused on the field of regenerative medicine. Co. is developing placenta-based cell therapy product candidates for the treatment of muscle trauma, hematological disorders, radiation damage and inflammation. Co.'s operations are focused on the research, development and manufacturing of cells, conducting clinical studies and the business development of cell therapeutics and cell based technologies, such as its collaboration with Tnuva Food Industries – Agricultural Cooperative in Israel Ltd.,through its fully owned subsidiary, Tnuva Food-Tech Incubator (2019), Limited Partnership, to use Co.'s technology to establish a cultured food platform. We show 4 historical shares outstanding datapoints in our PLUR shares outstanding history coverage, used to compute PLUR market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing PLUR market cap history over the course of time is important for investors
interested in comparing PLUR's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of PLUR versus a peer is one thing; comparing
PLUR market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like PLUR can fluctuate over the course of history.
With this page we aim to empower investors researching PLUR by allowing them to research the PLUR market cap history. |
Free PLUR Email Alerts:
Video: The Importance of Market Cap
